Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia

被引：17

作者：

Suzushima, Hitoshi ^{[1
]}

Wada, Naoko ^{[2
]}

Yamasaki, Hiroshi ^{[3
]}

Eto, Kenichiro ^{[4
]}

Shimomura, Taizo ^{[1
]}

Kugimiya, Michiko H. ^{[1
]}

Horikawa, Kentaro ^{[2
]}

Nishimura, Shintaro ^{[4
]}

Tsuda, Hiroyuki ^{[3
]}

Mitsuya, Hiroaki ^{[2
]}

Asou, Norio ^{[2
]}

机构：

[1] NTT W Kyushu Hosp, Dept Hematol & Immunol, Kumamoto 8628655, Japan

[2] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 860, Japan

[3] Kumamoto City Hosp, Dept Hematol & Oncol, Kumamoto, Japan

[4] Yatsushiro Gen Hosp, Dept Hematol, Yatsushiro, Japan

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 05期

关键词：

Elderly acute myeloid leukemia; Low-dose chemotherapy; Cytarabine; Aclarubicin; Granulocyte colony-stimulating factor; CAG; ACUTE MYELOGENOUS LEUKEMIA; RISK MYELODYSPLASTIC SYNDROME; OLDER-ADULTS; ARA-C; INDUCTION CHEMOTHERAPY; PROGNOSTIC-FACTORS; COMPLETE REMISSION; COOPERATIVE-GROUP; ONCOLOGY-GROUP; CAG REGIMEN;

D O I：

10.1016/j.leukres.2009.08.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 years were all registered. Thirty-three of 68 patients (49%) achieved remission. Median disease-free survival was 10 months and overall survival was nine months. Performance status after chemotherapy in patients who achieved remission was generally favorable. The present study demonstrates that CAG therapy is efficacious and well tolerated in the majority of elderly patients. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：610 / 614

页数：5

共 50 条

[1] Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia
Qian, Si-Xuan
Li, Jian-Yong
Tian, Tian
Shen, Yun-Feng
Jiang, Yuan-Qiang
Lu, Hua
Wu, Han-Xin
Zhang, Su-Iiang
Xu, Wei
[J]. LEUKEMIA RESEARCH, 2007, 31 (10) : 1383 - 1388
[2] Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia
Qian, S.
Li, J.
Zhang, S.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[3] Low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor for elderly patients with de novo acute myeloid leukemia
Chen, Chen
Xu, Wei
Yang, Jing
[J]. LEUKEMIA & LYMPHOMA, 2015, 56 (01) : 141 - 146
[4] Decitabine, low-dose cytarabine and aclarubicin combination with granulocyte colony-stimulating factor priming for the induction chemotherapy of older patients with myelodysplastic syndromes and acute myeloid leukemia
Qian, Sixuan
Zhang, Run
Zhu, Yu
Lu, Hua
Liu, Peng
Qiu, Hongxia
Wu, Hanxin
Hong, Ming
Li, Jianyong
[J]. BLOOD, 2012, 120 (21)
[5] Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia
Liu, Limin
Zhang, Yanming
Jin, Zhengming
Zhang, Xingxia
Zhao, Guangsheng
Si, Yejun
Lin, Guoqiang
Ma, Aidi
Sun, Yingxin
Wang, Li
Wu, Depei
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2014, 99 (05) : 603 - 608
[6] Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia
Limin Liu
Yanming Zhang
Zhengming Jin
Xingxia Zhang
Guangsheng Zhao
Yejun Si
Guoqiang Lin
Aidi Ma
Yingxin Sun
Li Wang
Depei Wu
[J]. International Journal of Hematology, 2014, 99 : 603 - 608
[7] Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21)
Wang, Ying
Li, Weiyang
Chen, Suning
Qiu, Huiying
Sun, Aining
Wu, Depei
[J]. LEUKEMIA RESEARCH, 2011, 35 (05) : 604 - 607
[8] Combination chemotherapy homoharringtonine, and granulocyte in patients with with low-dose cytarabine, colony-stimulating factor priming relapsed or refractory acute myeloid leukemia
Zhang, Wang-Gang
Wang, Fang-Xia
Chen, Yin-Xia
Cao, Xin-Mei
He, Al-Li
Liu, Jie
Ma, Xiao-Rong
Zhao, Wan-Hong
Liu, Su-Hu
Wang, Jian-Li
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2008, 83 (03) : 185 - 188
[9] Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor
Tatetsu, Hiro
Matsuno, Fumihiko
Takatsu, Noritaka
Miyake, Hirosada
Hoshino, Koyu
Nosaka, Kisato
Horikawa, Kentaro
Hata, Hiroyuki
Mitsuya, Hiroalci
Asou, Norio
[J]. LEUKEMIA RESEARCH, 2009, 33 (01) : 197 - 200
[10] Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia
Jin, Jie
Chen, Jian
Suo, Shanshan
Qian, Wenbin
Meng, Haitao
Mai, Wenyuan
Tong, Hongyan
Huang, Jian
Yu, Wenjuan
Wei, Juyin
Lou, Yinjun
[J]. LEUKEMIA & LYMPHOMA, 2015, 56 (06) : 1691 - 1697

← 1 2 3 4 5 →